Literature DB >> 24961611

Guideline. Diagnosis and treatment of venous malformations. consensus document of the international union of phlebology (iup): updated-2013.

B B Lee, I Baumgartner, P Berlien, G Bianchini, P Burrows, P Gloviczki, Y Huang, J Laredo, D A Loose, J Markovic, R Mattassi, K Parsi, E Rabe, M Rosenblatt, C Shortell, F Stillo, M Vaghi, L Villavicencio, P Zamboni.   

Abstract

Venous malformations (VMs) are the most common vascular developmental anomalies (birth defects). These defects are caused by developmental arrest of the venous system during various stages of embryogenesis. VMs remain a difficult diagnostic and therapeutic challenge due to the wide range of clinical presentations, unpredictable clinical course, erratic response to the treatment with high recurrence/persistence rates, high morbidity following nonspecific conventional treatment, and confusing terminology. The Consensus Panel reviewed the recent scientific literature up to the year 2013 to update a previous IUP Consensus (2009) on the same subject. ISSVA Classification with special merits for the differentiation between the congenital vascular malformation (CVM) and vascular tumors was reinforced with an additional review on syndrome-based classification. A "modified" Hamburg classification was adopted to emphasize the importance of extratruncular vs. truncular subtypes of VMs. This incorporated the embryological origin, morphological differences, unique characteristics, prognosis and recurrence rates of VMs based on this embryological classification. The definition and classification of VMs were strengthened with the addition of angiographic data that determines the hemodynamic characteristics, the anatomical pattern of draining veins and hence the risk of complication following sclerotherapy. The hemolymphatic malformations, a combined condition incorporating LMs and other CVMs, were illustratedas a separate topic to differentiate from isolated VMs and to rectify the existing confusion with namebased eponyms such as Klippel-Trenaunay syndrome. Contemporary concepts on VMs were updated with new data including genetic findings linked to the etiology of CVMs and chronic cerebrospinal venous insufficiency. Besides, newly established information on coagulopathy including the role of D-Dimer was thoroughly reviewed to provide guidelines on investigations and anticoagulation therapy in the management of VMs. Congenital vascular bone syndrome resulting in angio-osteo-hyper/hypotrophy and (lateral) marginal vein was separately reviewed. Background data on arterio-venous malformations was included to differentiate this anomaly from syndrome-based VMs. For the treatment, a new section on laser therapy and also a practical guideline for follow up assessment were added to strengthen the management principle of the multidisciplinary approach. All other therapeutic modalities were thoroughly updated to accommodate a changing concept through the years.

Entities:  

Year:  2014        PMID: 24961611

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  3 in total

1.  Percutaneous sclerotherapy for venous malformations in the extremities: clinical outcomes and predictors of patient satisfaction.

Authors:  Masahisa Nakamura; Keigo Osuga; Noboru Maeda; Hiroki Higashihara; Kenichiro Hamada; Nobuyuki Hashimoto; Shuichiro Uehara; Noriyuki Tomiyama
Journal:  Springerplus       Date:  2014-09-11

2.  Novel Compliant Scaffold with Specific Design for Venous System: Results of a Porcine Model Study.

Authors:  Pierfrancesco Veroux; Alessia Giaquinta; Carla Virgilio; Davide Danilo Zani; Giuliano Ravasio; Vincenzo Ardita; Paola Secchiero; Eugenio Scanziani; Paolo Zamboni; Massimiliano Veroux
Journal:  Biomed Res Int       Date:  2018-01-31       Impact factor: 3.411

3.  Calcium micro-depositions in jugular truncular venous malformations revealed by Synchrotron-based XRF imaging.

Authors:  Lorella Pascolo; Alessandra Gianoncelli; Clara Rizzardi; Veronica Tisato; Murielle Salomé; Carla Calligaro; Fabrizio Salvi; David Paterson; Paolo Zamboni
Journal:  Sci Rep       Date:  2014-10-07       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.